Dimensional Fund Advisors LP grew its position in Alder Biopharmaceuticals Inc (NASDAQ:ALDR) by 272.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 538,629 shares of the biopharmaceutical company’s stock after purchasing an additional 393,872 shares during the quarter. Dimensional Fund Advisors LP owned about 0.79% of Alder Biopharmaceuticals worth $6,598,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of ALDR. Janus Henderson Group PLC acquired a new stake in Alder Biopharmaceuticals during the second quarter worth approximately $36,956,000. Pictet Asset Management Ltd. grew its position in Alder Biopharmaceuticals by 159.4% during the third quarter. Pictet Asset Management Ltd. now owns 1,650,540 shares of the biopharmaceutical company’s stock worth $20,219,000 after buying an additional 1,014,290 shares in the last quarter. Schroder Investment Management Group acquired a new stake in Alder Biopharmaceuticals during the third quarter worth approximately $6,721,000. Ameriprise Financial Inc. grew its position in Alder Biopharmaceuticals by 287.2% during the second quarter. Ameriprise Financial Inc. now owns 619,938 shares of the biopharmaceutical company’s stock worth $7,098,000 after buying an additional 459,821 shares in the last quarter. Finally, Emerald Advisers Inc. PA grew its position in Alder Biopharmaceuticals by 32.2% during the third quarter. Emerald Advisers Inc. PA now owns 1,578,477 shares of the biopharmaceutical company’s stock worth $19,336,000 after buying an additional 384,805 shares in the last quarter. 97.22% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages recently issued reports on ALDR. ValuEngine downgraded Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Mizuho restated a “buy” rating and set a $29.00 target price on shares of Alder Biopharmaceuticals in a research note on Wednesday, January 31st. Canaccord Genuity set a $22.00 target price on Alder Biopharmaceuticals and gave the stock a “buy” rating in a research note on Friday, January 12th. Zacks Investment Research cut Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Finally, BMO Capital Markets upped their target price on Alder Biopharmaceuticals to $26.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 9th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company’s stock. Alder Biopharmaceuticals has a consensus rating of “Buy” and an average price target of $27.93.
Alder Biopharmaceuticals Inc (NASDAQ ALDR) opened at $13.55 on Friday. Alder Biopharmaceuticals Inc has a 12 month low of $8.60 and a 12 month high of $24.65. The company has a market capitalization of $953.21, a price-to-earnings ratio of -2.53 and a beta of 2.60.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/18/dimensional-fund-advisors-lp-raises-holdings-in-alder-biopharmaceuticals-inc-aldr.html.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.